Indications and Contraindications for Testosterone Therapy

Training Video In Production 

It Will Be Posted Soon

1) Therapy Framework: Why Indications And Contraindications Matter

A good start looks almost boring: clear impairment, repeat-confirmed deficiency under stable conditions, and a monitoring plan that fits real life. A bad start looks exciting: dramatic promises, fast dose changes, and a patient who measures success by a target number. Most clinics do not get into trouble because they chose the wrong ester, they get into trouble because the indication was weak and the boundaries were soft. Contraindications are not obstacles to revenue, they are guardrails that keep the practice medical. If you ignore guardrails, the next months become reactive medicine, which is the kind of medicine regulators and auditors don’t forgive.

A decision that is easy to explain is usually a decision that is easy to defend. When you can say, “Here’s why we’re starting, here’s what we’re watching, and here’s what would make us pause,” the entire relationship becomes calmer. ABCDS™ forces that clarity because it makes you look at prevention domains before you start the controlled substance. If those domains are unstable, you are not deciding “testosterone yes or no,” you are deciding “risk tolerance yes or no.” That shift keeps the clinic out of enhancement territory and keeps patients safer.

2) Defining Clinically Meaningful Symptoms And Functional Impairment

Symptoms need to be described in a way that survives time. “Low energy” and “brain fog” are real complaints, but they are not specific, and they overlap with sleep apnea, depression, anemia, thyroid dysfunction, medication effects, and plain sleep debt. The trick is to translate symptoms into function: what is failing, how often, and for how long. A patient who cannot recover from routine workouts, has persistent libido collapse, and has sustained fatigue despite stable sleep is a different story than a patient who is stressed, sleeping five hours, and wants to feel “alpha” again.

A simple habit that improves almost every evaluation is to write down two or three functional anchors you can revisit later. That prevents follow-up visits from becoming emotional debates and it prevents dose chasing disguised as “symptom management.”

Examples of usable functional anchors:

• Sleep continuity, including awakenings and morning restoration
• Libido stability and sexual function reliability across weeks
• Work capacity and afternoon energy crash frequency
• Training tolerance and recovery time after routine sessions
• Mood volatility, irritability spikes, and anxiety patterns

When the anchors are clear, you can tell whether the plan worked without relying on vibes. That protects the patient and protects the clinic.

3) Confirming Biochemical Deficiency: Repeat Testing, Timing, And Assay Discipline

Most mis-initiations start with a single lab drawn under bad conditions. Timing matters, sleep matters, illness matters, and alcohol matters, especially when values are borderline. Repeat confirmation under stable conditions is what separates careful medicine from “I saw a low number once.” If the patient is a shift worker, “morning” means after their sleep window, not after your clinic opens. If they were sick, sleep deprived, or traveling, that needs to be treated as a confounder, not as a diagnosis.

Practical testing discipline that prevents downstream chaos:

• Use repeat testing when results are borderline or when the story and lab don’t match
• Standardize the draw window to the patient’s sleep schedule
• Record last dose timing for anyone already exposed to androgens
• Avoid mixing labs and assays when you are trying to establish a baseline trend
• Don’t interpret a single snapshot like it’s a trajectory

ABCDS™ belongs here because cardiometabolic instability often explains symptoms better than hormones, and it also changes the risk tolerance for initiation. If the safety picture is unstable, rushing to “confirm a low number” can distract from the real work.

4) Total Testosterone, SHBG, And Free Testosterone: Avoiding Misclassification

Total testosterone can mislead you when SHBG is abnormal, and abnormal SHBG is common in real-world patients. Low SHBG states can make totals look low even when bioavailable androgen signaling is not the core issue, especially in obesity and insulin resistance. High SHBG states can make totals look “okay” while free levels and symptoms suggest a different picture. Free testosterone interpretation can help, but it can also become a new rabbit hole if clinicians order inconsistent methods and chase precision that the assay cannot deliver. The goal is consistent interpretation, not perfect interpretation.

The most common clinic mistake is diagnosing deficiency to match a symptom story without reconciling SHBG context. The second most common mistake is using free testosterone as a trophy number instead of using it as a context tool. If SHBG is driving the confusion, document that explicitly so future clinicians don’t restart the same debate. ABCDS™ often overlaps with SHBG issues because metabolic drift influences binding, symptoms, and risk tolerance all at once. When you interpret totals and SHBG cleanly, you reduce the chance that the patient starts therapy for the wrong reason.

5) Indications In Men: Organic Hypogonadism Versus Persistent Functional Suppression

Men with organic hypogonadism often have a durable pattern that stays abnormal even when confounders are cleaned up. In those cases, initiation can be straightforward, but the counseling still needs to be sober: this is long-horizon therapy with long-horizon monitoring. Persistent functional suppression is where clinics get into trouble, because reversibility is plausible, yet patients want immediate relief. Obesity, sleep apnea, depression, opioids, chronic illness, and chaotic sleep are common suppression drivers, and skipping that work creates a lifetime prescription that never fixes the real problem.

A staged plan is how you stay medical without sounding dismissive. If the patient’s drivers are obvious, correct drivers and retest under better conditions before calling it permanent. If symptoms and deficiency persist after stability improves, the probability shifts and therapy becomes more defensible. ABCDS™ gives you a stable way to explain why you are pausing for safety work, because patients can see that blood pressure, sleep stability, and metabolic drift matter. A disciplined approach protects against both errors: overtreating reversible suppression and missing true organic disease.

6) Indications In Women: Symptom Context, Dosing Boundaries, And Safety Priorities

Women require a different posture because dose sensitivity is higher and androgen-excess adverse effects can appear quickly. Indications should be narrower and grounded in symptom context and function, not in “optimize hormones” marketing language. Boundaries matter because a small overshoot can create acne, hair changes, voice effects, irritability, or cycle disruption that can be hard to unwind emotionally. A careful clinician explains that “more” is not the goal, and stability is the goal.

A common failure is importing male dosing habits and male target talk into female care. Another failure is letting a lab value become the reason to treat rather than using labs as context while symptoms and risk drive decisions. ABCDS™ still matters because cardiometabolic risk and sleep stability are not male-only issues, and they shape how safe any intervention is. Documenting dose boundaries and adverse-effect counseling protects continuity and protects the patient from whiplash changes driven by fear. A cautious start with clear stop criteria is usually the highest-integrity approach.

7) Absolute Contraindications And High-Risk Exclusions

Some scenarios should stop initiation because predictable harm outweighs likely benefit. A key one is refusal of monitoring, because prescribing without data is not defensible medical care. Another is uncontrolled or untreated high-risk sleep apnea suspicion paired with unstable symptoms or rising hematocrit history, because that combination can drift quickly. Another is clear enhancement intent with no medical necessity, because the clinic becomes an optimization service the moment it agrees. Severe psychiatric instability also belongs here when it makes adherence unreliable or when it increases impulsive escalation pressure.

High-risk exclusions should be handled consistently and calmly. The patient should leave with a plan, but the plan should not be testosterone when the prerequisites for safe therapy are missing. ABCDS™ supports this because it allows the clinician to point to safety domains rather than personal judgment. Documentation should be factual, because emotional notes undermine credibility. When exclusions are applied predictably, patients are less likely to fight, because they see rules rather than moods. The goal is to protect the patient and protect the practice from preventable harm.

8) Relative Contraindications And Risk Mitigation Planning

Most real patients live in the gray zone, not in the textbook. Relative contraindications are not automatic “no,” but they are clear “not yet” until risk is stabilized. Examples include borderline blood pressure, rising hematocrit trends, inconsistent follow-through history, untreated sleep disruption, or mixed motives that need clearer boundaries. The safest approach is to identify what must be corrected before therapy is defensible, then set a timeline to reassess. A plan without a timeline turns into drift, and drift becomes conflict.

Risk mitigation should be measurable. Stabilize sleep. Coordinate blood pressure management. Reduce stimulant dependence that fragments sleep and raises pressure. Clean up medications that confound libido and fatigue. Use ABCDS™ as the organizing map so patient and clinician are talking about the same safety domains. Patients accept “not yet” better when they see a pathway and a checkpoint, not an open-ended delay. Done well, risk mitigation reduces adverse events and strengthens patient trust.

9) Fertility Goals And Reproductive Counseling Before Initiation

Fertility counseling is required because exogenous testosterone suppresses spermatogenesis reliably. Many patients say fertility does not matter until life changes, and regret is common when this topic is skipped. The simplest rule is to talk about fertility before you prescribe, not after symptoms improve and the patient feels committed. Document the conversation because it is one of the most common dispute points later. Counseling should include the reality that recovery can be variable and that planning is easier before exposure begins.

Fertility goals also influence whether therapy is the right next step when functional suppression is likely. In men who want children, alternatives and staged driver correction often become the first-line plan. In women, reproductive planning intersects with broader endocrine decisions that require tight dosing boundaries and careful follow-up. ABCDS™ still matters because metabolic health and sleep stability affect fertility and risk tolerance. A clear fertility discussion protects long-horizon options and prevents future conflict.

10) Baseline Evaluation Checklist Using ABCDS™

Baseline evaluation should be structured so follow-up is interpretable and so the start is defensible. ABCDS™ provides a natural baseline checklist lens because it forces attention to prevention domains that drift silently. The baseline is not only about eligibility, it’s about establishing a reference point that makes later decisions easier.

Baseline checklist using ABCDS™ plus practical essentials:

• Glycemic trajectory: weight trend, A1C or fasting glucose context when relevant
• Blood pressure: reliable readings, home cuff quality, control status
• Lipids: baseline pattern and prevention plan when indicated
• Hematocrit and hemoglobin: baseline and trend, plus sleep and hydration context
• Sleep stability: apnea risk screen, insomnia pattern, stimulant use
• Symptom baseline: two or three functional anchors you will reassess
• Medication review: confounders, fertility-impacting agents, controlled substances exposure
• Follow-up feasibility: the patient’s ability to return and complete labs on schedule

This checklist makes counseling easier because the patient sees that the plan is broader than a single hormone.

11) Shared Decision Making And Documentation Standards For Initiation

Shared decision making should look like structure, not like a vague agreement. The patient should understand responsibilities, tradeoffs, monitoring cadence, and what triggers pausing or stopping. The clinician should document what was discussed in plain language, because disputes often center on what the patient believes was promised. A clear record also helps future clinicians maintain continuity without reopening old negotiations.

Documentation elements that keep initiation defensible:

• Indication stated in functional terms and linked to symptom timeline
• Biochemical confirmation method and timing discipline, including repeat testing
• ABCDS™ baseline and the monitoring cadence agreed upon
• Fertility counseling summary when relevant
• Follow-up date and what will be reassessed
• Stop criteria and pause criteria tied to benefit and safety drift

The record should read like medicine, not like marketing, and it should make the next decision point obvious.

12) When To Defer Therapy And What To Do Instead

Deferral is a clinical decision, not a failure, and it should come with a real plan. Many patients improve more from addressing sleep apnea risk, obesity, depression, overtraining, or medication confounders than from immediate testosterone exposure. Deferral should be time-bound with milestones so the patient feels supported rather than dismissed. A vague “come back later” plan drives unsafe sourcing behavior and undermines trust.

What to do instead should be specific: sleep evaluation, metabolic work, medication coordination, mental health support, and treatment of comorbid disease. ABCDS™ can show progress even when testosterone is not prescribed, because domain improvement often improves symptoms. Retesting should occur after stability improves so data becomes more meaningful. The goal is to treat the problem, not to satisfy urgency.

13) Red Flags After Initiation: When To Pause, Adjust, Or Stop

Early red flags should trigger structure, not escalation. Rising hematocrit, worsening blood pressure, sleep deterioration, mood destabilization, or repeated missed monitoring are common early trouble patterns. Some red flags are delivery-system problems, such as volatility-driven insomnia, and they may respond to frequency adjustment rather than dose escalation. Other red flags are ABCDS™ drift problems where prevention markers worsen despite symptom improvement. When oversight breaks down, pauses protect safety and preserve long-term options.

Red flag response rules that prevent drift:

• If monitoring is missed repeatedly, pause until safety data is restored.
• If hematocrit rises, address peaks and sleep stability before chasing quick procedural fixes.
• If blood pressure drifts, coordinate prevention work and avoid escalation that worsens fluid shifts.
• If sleep worsens, treat sleep drivers before treating fatigue with higher dose.
• If mood destabilizes, stabilize the curve and reassess mental health drivers before layering medications.

When benefit is absent and risk rises, stopping can be more ethical than continuing out of habit.

14) Course Summary

Initiation decisions are where clinics either maintain medical integrity or drift into permissive, hard-to-defend prescribing. Clinically meaningful symptoms must be defined in functional terms and linked to a timeline that supports differential diagnosis. Biochemical deficiency requires repeat confirmation under stable conditions with timing discipline that makes trends interpretable. SHBG context can change interpretation and must be handled carefully to avoid misclassification. Indications differ for men and women, and women require tighter dosing boundaries and higher sensitivity awareness. Absolute contraindications require consistent refusal, while relative contraindications require measurable risk mitigation planning. Fertility counseling is required before initiation because exogenous testosterone predictably suppresses spermatogenesis and can create future regret. ABCDS™ provides the baseline and monitoring backbone so safety domains remain visible from the first decision forward. Shared decision making and documentation standards make the reasoning chain defensible and preserve continuity. Deferral pathways should be active and specific rather than vague, because deferral without a plan drives unsafe sourcing. Red flag response after initiation should be structured, because early drift is easier to correct than late crisis. The result is safer initiation, fewer preventable adverse events, and stronger credibility over long-term care.

Recommended Grand Rounds Case Reviews